Mersana Therapeutics Inc (NASDAQ: MRSN) Could Be Viewed Differently By Investors Because Of These Numbers

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Recently, Yahoo Finance discussed the stock, revealing that Mersana Therapeutics to Participate in Guggenheim’s 6th Annual Biotechnology Conference.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Stocks Info

The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Mersana Therapeutics Inc is $473.88M. A total of 2.14 million shares were traded on the day, compared to an average of 1.11 shares.

Insider Activity

Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, MRSN has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 16 BUYs and 3 SELLs from insiders. Insiders purchased 174,616 shares during that period but sold 7,764.

In the most recent transaction, Protopapas Anna sold 29,399 shares of MRSN for 2.71 per share on Jan 16. After the transaction, the Director now owns 125,153 company shares. In a previous transaction on Jan 16, Lowinger Timothy B sold 10,409 shares at 2.71 per share. MRSN shares that SVP, Chief Sci.&Tech. Officer owns now total 199,329.

Among the insiders who sold shares, DeSchuytner Brian disposed of 9,327 shares on Jan 16 at a per-share price of $2.71. This resulted in the SVP, COO & CFO holding 54,511 shares of MRSN after the transaction. In another insider transaction, Mandelia Ashish sold 5,025 shares at $2.71 per share on Jan 16. Company shares held by the VP, Chief Accounting Officer now total 23,328.

It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for MRSN in the last 3 months, the mean price target is $3.00 with high estimates of $5.00 and low estimates of $1.00. In terms of 52-week highs and lows, MRSN has a high of $9.62 and a low of $0.80.

As of this writing, MRSN has an earnings estimate of -$0.21 per share for the current quarter. EPS was calculated based on a consensus of 8 estimates, with a high estimate of -$0.14 per share and a lower estimate of -$0.28. The company reported an EPS of -$0.47 in the last quarter, which was -6.80% lower than expectations of -$0.44.

Balance Sheet Annually/Quarterly

An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. MRSN’s latest balance sheet shows that the firm has $177.95M in Cash & Short Term Investments as of fiscal 2021. There were $38.18M in debt and $47.52M in liabilities at the time. Its Book Value Per Share was $0.43, while its Total Shareholder’s Equity was $121.74M.

Analysts Opinion

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MRSN is Buy with a score of 3.44.

Most Popular

Related Posts